Virologic Outcomes After LA ART Initiation with and without Viremia in Two Large U.S. Clinic Cohorts.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 42372087.
- Also identified by DOI 10.1093/cid/ciag392.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Long-acting cabotegravir/rilpivirine supports virologic suppression among people with HIV (PWH) facing adherence challenges. In two large U.S. cohorts(n=1,070), 96% of viremic PWH achieved virologic suppression at a 4-week median. However, blips/failure were more frequent among PWH initiating with viremia, underscoring the need for careful monitoring and optimization of long-acting treatment.